2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Recruiting
5
Unknown
3
Withdrawn
2
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
NET
2
Endocrine
2
Gastrointestinal
1
Conditions
Neuroendocrine Tumors
2
Gastro-enteropancreatic neuroendocrine tumor
1
Interventions
pembrolizumab
439
Carboplatin
323
Nivolumab
291
Cyclophosphamide
281
Specimen Handling
271
Magnetic Resonance Spectroscopy
257
Cisplatin
254
Paclitaxel
249
Radiotherapy
229
Gemcitabine
183
Biopsy
182
Dexamethasone
181
durvalumab
169
atezolizumab
151
Rituximab
138
Doxorubicin
135
Lenalidomide
134
Bevacizumab
133
Docetaxel
131
Ipilimumab
129
Capecitabine
120
Radiation
118
Radiosurgery
114
Oxaliplatin
114
Pemetrexed
113
Etoposide
111
Fluorouracil
110
venetoclax
108
fludarabine
106
Prednisone
97
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Active not recruiting
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT03049189
2026-04-06
COMPETE
ITM Solucin GmbH
Phase 3
Active not recruiting
324 enrolled
15 charts
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled